Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease
Authors:
- Andrzej RadzikowskiARAndrzej Radzikowski
- Aleksandra BanaszkiewiczABAleksandra Banaszkiewicz
- Izabella Łazowska-PrzeorekIŁIzabella Łazowska-Przeorek
- Urszula Grzybowska-ChlebowczykUGUrszula Grzybowska-Chlebowczyk
- Halina WośHWHalina Woś
- Tomasz PytrusTPTomasz Pytrus
- Barbara IwańczakBIBarbara Iwańczak
- Kinga Kowalska-DuplagaKKKinga Kowalska-Duplaga
- Krzysztof FyderekKFKrzysztof Fyderek
- Agnieszka GawrońskaAGAgnieszka Gawrońska
- Katarzyna Karolewska-BochenekKKKatarzyna Karolewska-Bochenek
- Maria KotowskaMKMaria Kotowska
- 1 May 2011
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (5) , 1117-1124
Abstract
There are only a few studies on immune response to routine vaccinations in children with inflammatory bowel disease (IBD), despite a strong need for this kind of study. The aim of the study was to evaluate the immunogenicity of an inactivated hepatitis A vaccine (HAV) in IBD pediatric patients compared with healthy controls. This was an open, prospective, and controlled study on anti-HAV-negative children and adolescents age 2-18 years with IBD. HAV using 720 enzyme-linked immunosorbent assay (ELISA) units were administered at 0 months and at 6-12 months. Seroconversion and geometric mean titers were measured after each vaccine dose. The evidence of local and systemic adverse effects for 3 days after the first and second dose of vaccine was registered. A total of 134 subjects (66 patients and 68 controls) completed the whole study course consisting of two doses of vaccine and six serum samples. There was no significant difference in the rate of seroconversion between IBD patients and controls when measured after the second dose of vaccine (97% versus 100%, P = 0.2407), but the rate was significantly lower in the IBD group when measured after the first dose (39% versus 64%, P = 0.00001). The mean geometric titers were statistically significantly lower in the IBD group than in the control group at all of the measured timepoints. There were no serious adverse events related to HAV during the study. HAV is both immunogenic and safe in pediatric patients with IBD.Keywords
This publication has 23 references indexed in Scilit:
- Immunosuppression Impairs Response to Pneumococcal Polysaccharide Vaccination in Patients With Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2010
- Review article: inflammatory bowel disease and geneticsAlimentary Pharmacology & Therapeutics, 2007
- Immune Response to Influenza Vaccine in Pediatric Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2007
- Failure to Respond to Hepatitis B Vaccine in Children With Celiac DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2007
- Extraintestinal manifestations and complications in inflammatory bowel diseasesWorld Journal of Gastroenterology, 2006
- Methods to Avoid Infections in Patients with Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2005
- Guidelines for Immunizations in Patients With Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2004
- Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis CNew England Journal of Medicine, 1998
- Inflammatory Bowel Disease in Children and AdolescentsPediatric Annals, 1997
- Defective generation of tetanus-specific antibody-producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patientsGastroenterology, 1985